XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment   2    
Segment Reporting Information [Line Items]        
Revenues   $ 2,743.3 $ 2,539.3 $ 2,225.1
Adjusted EBITDA   438.1 380.2 339.6
Reconciliation of Adjusted EBITDA:        
Income (loss) before income taxes   135.0 110.3 81.2
Net income attributable to non-controlling interests   (147.2) (141.6) (141.6)
Interest expense, net   193.0 234.9 221.0
Depreciation and amortization   118.1 114.8 98.8
Equity-based compensation expense   17.7 18.4 17.4
Transaction, integration and acquisition costs   64.9 48.6 46.1
Net loss on disposals, consolidations and deconsolidations   14.4 11.1 2.2
Litigation settlements and regulatory change impact   17.5 (24.7) 5.6
Loss on debt extinguishment   15.5 14.9 9.1
Undesignated derivative activity   0.6 (8.0) 0.0
Other   8.6 1.5 (0.2)
Transaction and integration costs   61.7 47.5 39.8
Start-up costs   3.2 1.1 6.3
(Loss) gain on litigation settlement $ 32.8 (10.6) 29.3 0.0
Other litigation costs   2.5 4.6 5.6
Additional interest expense for Florida LOP regulation change   4.4    
Derivatives not designated as hedging instruments        
Reconciliation of Adjusted EBITDA:        
(Gain) loss recognized in income   7.5    
Operating Segments | Surgical Facility Services        
Segment Reporting Information [Line Items]        
Revenues   2,675.8 2,470.4 2,157.8
Adjusted EBITDA   544.0 473.6 422.0
Operating Segments | Ancillary Services        
Segment Reporting Information [Line Items]        
Revenues   67.5 68.9 67.3
Adjusted EBITDA   (3.9) (2.3) 1.7
All other        
Segment Reporting Information [Line Items]        
Adjusted EBITDA   $ (102.0) $ (91.1) $ (84.1)